Literature DB >> 9363858

Chemotherapy for advanced gastric cancer: where do we stand?

C S Fuchs.   

Abstract

Entities:  

Mesh：

Year:  1997        PMID： 9363858     DOI： 10.1200/JCO.1997.15.11.3299

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Histopathological assessment of multidrug resistance in gastric cancer: expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein.

Authors:  D Alexander; T Yamamoto; S Kato; S Kasai
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Bimonthly 24 h infusion of high-dose 5-fluorouracil vs EAP regimen in patients with advanced gastric cancer. A randomized phase II study.

Authors:  I P Popov; S B Jelić; Z V Krivokapić; S D Jezdić; P M Pesko; M T Micev; D R Babić
Journal:  Med Oncol       Date:  2007-11-01       Impact factor: 3.064

3.  Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer.

Authors:  G V Kornek; M Raderer; B Schüll; W Fiebiger; C Gedlicka; A Lenauer; D Depisch; B Schneeweiss; F Lang; W Scheithauer
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.